CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infarc
See the full post here as oringinally posted on this site.
